Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Silverstrand Investments v. Amag Pharmaceuticals, Inc. et al
Case Number:
1:10-cv-10470
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
Companies
Sectors & Industries:
-
April 09, 2014
AMAG Pharma Fails To Shirk Drug-Risks Investor Suit
A Massachusetts federal court rejected a motion to dismiss a putative class action accusing AMAG Pharmaceuticals Inc. and its bank underwriters of misleading investors about the risks of iron deficiency treatment Feraheme, ruling Monday that the suit could continue in light of the First Circuit's reviving the case.
-
August 15, 2011
Judge Boots Investor Class Action Over Feraheme Risks
A Massachusetts federal judge on Thursday tossed a putative class action brought by AMAG Pharmaceuticals Inc. shareholders against the company and its underwriters for allegedly misleading investors about the risks associated with AMAG's injectable iron deficiency treatment Feraheme.